Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodoproxyfan SCHEMBL3085830 | 0.89 | HRH3 (0.46) | HRH3HRH4 | |
| SCHEMBL7971701 | 0.86 | HRH3 (0.40) | HRH3HRH4IDO1 | |
| Proxyfan SCHEMBL4072620 | 0.85 | HRH3 (0.54) | HRH3HRH4 | |
| SCHEMBL7988330 | 0.82 | HRH3 (0.38) | HRH3HRH4 | |
| SCHEMBL14027508 | 0.80 | SPHK2 (0.34) | HRH3HRH4APP | |
| Proxyfan SCHEMBL15130144 | 0.80 | HRH3 (0.48) | HRH3HRH4 | |
| SCHEMBL7977176 | 0.79 | HRH3 (0.36) | HRH3HRH4 | |
| SCHEMBL7988978 | 0.79 | GBA1 (0.41) | HRH3HRH4 | |
| SCHEMBL8107511 | 0.78 | HRH4 (0.46) | HRH3HRH4 | |
| SCHEMBL8104619 | 0.77 | HRH4 (0.54) | HRH3HRH4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | claimed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-8492375-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2013-07-23 | — | — | US | disclosed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2186516-B1 | Novel benzazepine derivative | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-7846922-B2 | 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists | GLAXO GROUP LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| EP-2186516-A1 | Novel benzazepine derivative | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| WO-2004037800-A1 | ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004035544-A1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035556-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| EP-0597088-A1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993014070-A2 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885HRH4 518/4885APP 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.